Krebs Biochemicals & Industries Ltd

AGM Details

• Held on 29 September 2026 at 11:30 AM via VC/OAVM.

Key Resolutions

• Adopt audited financial statements and reports for FY2026.
• Re-appoint Dr. R T Ravi as director on rotation.
• Re-appoint Milanish Kumar Jain as director on rotation.
• Approve related party transactions with IPCA Laboratories Limited.
• Ratify remuneration payable to Cost Auditors.

Voting Results

• Resolution 1 passed by requisite majority.
• Resolution 2 passed by requisite majority.
• Resolution 3 passed by requisite majority.
• Resolution 4 passed by requisite majority.
• Resolution 5 passed by requisite majority.

Directors

• Dr. R T Ravi reappointed as director.
• Milanish Kumar Jain reappointed as director.

Auditors

• Remuneration payable to Cost Auditors ratified.

Related Party Transactions

• IPCA Laboratories Limited related party transactions approved.

AGM details

• AGM held on 29 September 2026 at 11:30 a.m. via VC/OAVM.
• E-voting conducted 25–28 September 2026.

Resolutions

• Ordinary: adopt annual financial statements for year ended 31 March 2026.
• Ordinary: re-appointment of Dr. R T Ravi (retiring by rotation).
• Ordinary: re-appointment of Manish Kumar Jain (retiring by rotation).
• Special: approve related party transactions with Ipca Laboratories Limited.
• Special: ratify remuneration of Cost Auditors.

Voting status

• Voting results to be declared after scrutiny; not disclosed in filing.

Krebs Biochemicals & Industries Limited — Trading Window Closed from close of business on September 30, 2026 until 48 hours after declaration of Unaudited Financial Results for the quarter and half year ended September 30, 2026

Financial results

• Revenue from operations: ₹698.35 lacs; total income: ₹714.00 lacs.
• Total expenses: ₹962.48 lacs; loss before tax: ₹248.48 lacs.
• Results reviewed by Audit Committee and approved by Board for the quarter ended 30 Jun 2026.

Amalgamation with IPCA Laboratories

• Board approved amalgamation with IPCA Laboratories Limited; appointed date: 1 April 2026.
• Subject to necessary consents/ approvals for completion.

Operational update – Vizag unit

• Vizag manufacturing unit remains closed under APPCB order dated 7 Feb 2025.
• Company is in dialogue with PCB seeking revocation of the order.

Governance & regulatory notes

• Quarterly results reviewed by Audit Committee and approved by Board on Aug 6, 2026.
• Independent Auditor's Review Report issued; no material misstatement identified.
• As of 30 Jun 2026, no subsidiary/associate/joint venture.

Q1 FY2026-27 results

• Board approves unaudited quarterly results for quarter ended June 30, 2026.
• Limited Review Report by auditors on Q1 2026 unaudited results.

Meeting Details

• Board meeting scheduled for August 6, 2026.
• Agenda: consider unaudited Q1 2026 results (quarter ended June 30, 2026).

Key Agenda Items

• Consider and adopt unaudited financial results for the quarter ended June 30, 2026.

Other Notes

• Trading window closure period noted for insiders.

Certificate status

• Details of dematerialised/rematerialised securities furnished to all stock exchanges.
• Certificate confirms furnishing of such details to all stock exchanges.